1–10 of 76 results for AMD-Non-Neovascular
Expert Panel: Pegcetacoplan Safety
Andre J. Witkin, MD
David A. Eichenbaum, MD, FASRS
Samuel Anthony Minaker, MD, MSc
Janani Singaravelu, MS, MD
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2024
Anatomic Changes Following a Single Injection of AVD-104 in Patients With GA Secondary to AMD in the SIGLEC Study
David S. Boyer, MD
Protective Effects of ANX007 on Central Macular Ellipsoid Zone (EZ) and Retinal Pigment Epithelium (RPE) and Association with Visual Acuity in the Phase 2 ARCHER GA Study
Glenn J. Jaffe, MD
Impact of Vitrectomy Surgery on the Progression of Age-Related Macular Degeneration
Association of Metformin Use and New-Onset of ICD-Coding of Geographic Atrophy
Dimitra Skondra, MD,PhD
Quantitative Contrast Sensitivity Longitudinal Changes Correlate Better Than Visual Acuity With Geographic Atrophy Progression
John B. Miller, MD
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial
Joel Pearlman, MD, PhD
Pooled Safety Analysis and Immunogenicity of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With AMD
Christine Kay, MD
Results From Part 1 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for Geographic Atrophy: Glyco-immunologic Modulation of Macrophage Activity
Rishi P. Singh, MD